Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Period	fcf
2015-12-31	-$45.35M
2016-12-31	-$44.16M
2017-12-31	-$25.71M
2018-12-31	-$25.57M
2019-12-31	-$37.74M
2020-12-31	-$28.13M
2021-12-31	-$57.33M
2022-12-31	-$93.19M
2023-12-31	-$46.12M
2024-12-31	-$151.81M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LAB	$0.93	+0.32%	1.04M
3
4
5

Standard BioTools Inc. (LAB) Free Cash Flow

Free Cash Flow Data

Get Standard BioTools Inc. Data in Excel

More LAB Financial Data